Xcout Intel
NeuroEM Therapeutics, Inc.
NeuroEM Therapeutics develops non-invasive medical technology to treat Alzheimer's disease. The company utilizes Transcranial Electromagnetic Treatment with Radio Frequencies (TEMT-RF) to target toxic brain proteins associated with cognitive decline in patients.
Subscribe to see NeuroEM Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NeuroEM Therapeutics, Inc. at a glance
NeuroEM Therapeutics, Inc. is a medical device company headquartered in United States. Its most recent funding round, Series A, raised $1.3M in June 2025. Xcout tracks 9 named people at NeuroEM Therapeutics, Inc., including Chuck Papageorgiou (Chief Executive & Technical Officer).
NeuroEM Therapeutics, Inc. leadership
- Chuck PapageorgiouChief Executive & Technical Officer
- Edward Goodwin, PhDChief Science Officer
- Rob BaranowskiChief Engineer
- Sam Alex MulderChief of Staff
- Tracy IngramChief Operating & Information Officer
- William Scott Burgin, MDChief Medical Officer
3 more named people on record for NeuroEM Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
NeuroEM Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $1.3M | 2 named | |
| SEC Form D filing | $1.9M | — | |
| Series A | $2M | 1 named | |
| SEC Form D filing | $360,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
NeuroEM Therapeutics, Inc. competitors
A few of NeuroEM Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
NeuroThera develops a clinical-grade transcranial photobiomodulation platform that delivers near-infrared laser light to targeted brain regions. The company's non-invasive technology aims to treat major neurological and psychiatric conditions, including major depressive disorder, Alzheimer's disease, Parkinson's disease, traumatic brain injury, and stroke recovery.
NeuroReform Holdings develops the NeuroReformer, an FDA-cleared Class II medical device that uses patented scanning technology to measure individual patient frequencies and deliver personalized neuromuscular stimulation during movement. The company serves healthcare professionals across physical therapy, sports medicine, chiropractic, podiatry, and wellness sectors through a monthly lease model.
NeuroGlove, LLC develops a novel medical device designed to treat a variety of neurological and psychological conditions, including stroke, Parkinson's disease, PTSD, traumatic brain injury, anxiety, depression, and insomnia. The company serves patients and healthcare sectors by providing innovative treatment options aimed at transforming healthcare.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Cognition Med, LLC develops interventional neurovascular medical devices designed to treat stroke patients through minimally-invasive endovascular procedures. The company focuses on creating technologies to remove blood clots from blood vessels in the brain.
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Get NeuroEM Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NeuroEM Therapeutics, Inc. in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access